OTTAWA, June 2 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or
"the Company") released today additional results of animal studies indicating
effectiveness of its lead cancer drug, PhG-alpha-1, in treating two types of
highly aggressive human colon cancer. These results are consistent with and
augment earlier results using breast and colon cancers announced by the
Company on April 17, 2008.
The two human cancer cell lines used are both colorectal cancers which
are known to be aggressive and difficult to successfully treat.
In these final two of five human cancer models studied, a total of
100 mice in which human colon cancer cells of two different types had
previously been implanted subcutaneously and allowed to grow into solid body
tumours of a palpable size were then treated with PhG-alpha-1 at three doses
(1, 5, and 10 mg/kg body weight), both singly and in combination with
chemotherapeutic agents, or received saline solution or the chemotherapeutic
agent alone as test controls.
The results indicate an extension of survival and reduction of tumour
volume in groups treated with PhG-alpha-1, alone and in combination with
Robert McInnis, President & CEO commented "We are delighted with this
additional compelling evidence of efficacy seen with our lead compound in
these most recent results. These cancers are both aggressive and
representative of cancers found in real patients. These additional test
results add to the body of evidence that PhG-alpha-1 has the potential to be
developed into an effective agent against cancer in humans."
Colon Cancer (early stage type) subcutaneous model
Human colon cancer cells type LS180, known to be highly invasive, were
implanted beneath the skin and provided time to develop palpable tumours,
following which treatment began.
The group receiving PhG-alpha-1 both singly and in combination treatment
exhibited an extension of survival when compared to the group receiving
chemotherapy alone. Average days survival following commencement of treatment
was 31 for the group receiving chemotherapy alone (with a maximum of 37 days),
extended by almost 30% to 40 days in the groups receiving PhG-alpha-1 alone
(with a maximum of 56 days), and 32 days in the groups receiving combined
treatment (with a maximum of 47 days).
In the group receiving the chemotherapy treatment alone, average tumour
volume of 1,000 cubic mm was reached in 26 days, compared to 33 days (26%
slower) for the combined treatments at PhG-alpha-1 doses of 5 and 10 mg/kg,
and 44 days (69% slower) for groups treated with PhG-alpha-1 alone at each of
the 3 doses. Moreover, the average tumour size at time of euthanasia was
3,681 cubic mm for the group receiving the chemotherapy alone, 2,929 cubic mm
for all combined treatment groups, and 2,417 cubic mm for the groups receiving
PhG-alpha-1 alone. The overall reduction in tumour volume compared to the
control group receiving chemotherapy alone was approximately 20% for combined
treatments and approximately 34% for groups treated with PhG-alpha-1 alone.
Colon Cancer (later stage type) subcutaneous model
A later stage human colon cancer cell line, known to be highly drug
resistant, was implanted beneath the skin and provided time to develop
palpable tumours, following which treatment began. In earlier in vitro testing
at Memorial Sloan Kettering Cancer Center in New York, PhG-alpha-1 was shown
to have a strong effect against this cell line, increasing the efficacy of the
chemotherapy agent used by 50%.
This cancer cell line is known to exhibit very slow growth, resulting in
a lower number of tumour occurrences in this test cohort. In this current
test, observations of mice in which tumours did develop show a positive effect
of the combined treatment using PhG-alpha-1 when compared to the mice
receiving chemotherapy alone, on both extension of survival and limitation of
tumour volume. In ex vivo examination of cells obtained from the tumours,
those obtained from the tumours from the combined treatment groups exhibited a
very low yield of viable cells compared to the chemotherapy alone group, an
additional indicator of effectiveness of the combined PhG-alpha-1 treatment.
Overall, these results are consistent with and support those obtained earlier
at Memorial Sloan Kettering Cancer Center.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology
company with a core focus on developing novel therapeutic compounds for the
treatment of cancer. PharmaGap's research platform targets cellular signalling
pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug
compound, PhG-alpha-1, is in preclinical development and targets PKC alpha.
The Company's strategy is to out-license drug compounds to larger life
sciences companies at the preclinical stage. For more information on PharmaGap
please visit the Company's website at www.pharmagap.com.
Note: The TSX-Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has approved or
disapproved of the information contained herein. This release contains forward
looking statements that may not occur or may change materially.
For further information:
For further information: relating to this Release: Robert McInnis,
President & CEO, (613) 990-9551, firstname.lastname@example.org